Matt Clancy on innovation, progress studies and remote work.
Ben Yeoh Chats
00:00
The Biggest Thing About mRNA for Malaria
We might have mRNA for malaria but arguably it's been a bit slow and that is essentially because countries which have malaria aren't going to pay very much money for it so there's this profit they can even though you've got some advanced purchase. I actually think incidentally on over the long run it might prove a net slightly advantageous that mRNA came through now as my current reading is if it wasn't for something acute the regulators would have asked for so much data now like well how much mRNA data would you want have wanted before you could prove it would work?
Transcript
Play full episode
